HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, R. R. Articles by Jensen, R. T. Search for Related Content PubMed PubMed Citation Articles by Ryan, R. R. Articles by Jensen, R. T. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 22, 13613-13624, May 29, 1998

Ability of Various Bombesin Receptor Agonists and Antagonists to Alter Intracellular Signaling of the Human Orphan Receptor BRS-3

Richard R. Ryan, H. Christian Weber, Wei Hou, Eduardo Sainz^§, Samuel A. Mantey, James F. Battey^§, David H. Coy^¶, and Robert T. Jensen

From the  Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, ^§ NIDCD, National Institutes of Health, Rockville, Maryland 20892, and ^¶ Peptide Research Laboratories, Tulane University Medical Center, New Orleans, Louisiana 70112

Bombesin (Bn) receptor subtype 3 (BRS-3) is an orphan receptor that is a predicted member of the heptahelical G-protein receptor family and so named because it shares a 50% amino acid homology with receptors for the mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide. In a recent targeted disruption study, in which BRS-3-deficient mice were generated, the mice developed obesity, diabetes, and hypertension. To date, BRS-3's natural ligand remains unknown, its pharmacology unclear, and cellular basis of action undetermined. Furthermore, there are few tissues or cell lines found that express sufficient levels of BRS-3 protein for study. To define the intracellular signaling properties of BRS-3, we examined the ability of [D-Phe⁶,-Ala¹¹,Phe¹³,Nle¹⁴]Bn-(6-14), a newly discovered peptide with high affinity for BRS-3, and various Bn receptor agonists and antagonists to alter cellular function in hBRS-3-transfected BALB 3T3 cells and hBRS-3-transfected NCI-H1299 non-small cell lung cancer cells, which natively express very low levels of hBRS-3. This ligand stimulated a 4-9-fold increase in [³H]inositol phosphate formation in both cell lines under conditions where it caused no stimulation in untransfected cells and also stimulated an increase in [³H]IP₁, [³H]IP₂, and ³H]IP₃. The elevation of [³H]IP was concentration-dependent, with an EC₅₀ of 20-35 nM in both cell lines. [D-Phe⁶,-Ala¹¹,Phe¹³,Nle¹⁴]Bn-(6-14) stimulated a 2-3-fold increase in [Ca²⁺]_i, a 3-fold increase in tyrosine phosphorylation of p125^FAK with an EC₅₀ of 0.2-0.7 nM, but failed to either stimulate increases in cyclic AMP or inhibit forskolin-stimulated increases. None of nine naturally occurring Bn peptides or three synthetic Bn analogues reported to activate hBRS-3 did so with high affinity. No high affinity Bn receptor antagonists had high affinity for the hBRS-3 receptor, although two low affinity antagonists for gastrin-releasing peptide and NMB receptors, [D-Arg¹,D-Trp^7,9,Leu¹¹]substance P and [D-Pro⁴,D-Trp^7,9,10]substance P-(4-11), inhibited hBRS-3 receptor activation. The NMB receptor-specific antagonist D-Nal,Cys,Tyr,D-Trp,Lys,Val, Cys,Nal-NH₂ inhibited hBRS-3 receptor activation in a competitive fashion (K_i = 0.5 µM). Stimulation of p125^FAK tyrosine phosphorylation by hBRS-3 activation was not inhibited by the protein kinase C inhibitor, GF109203X, or thapsigargin, alone or in combination. These results show that hBRS-3 receptor activation increases phospholipase C activity, which causes generation of inositol phosphates and changes in [Ca²⁺]_i and is also coupled to tyrosine kinase activation, but is not coupled to adenylate cyclase activation or inhibition. hBRS-3 receptor activation results in tyrosine phosphorylation of p125^FAK, and it is not dependent on activation of either limb of the phospholipase C cascade. Although the natural ligand is not a known bombesin-related peptide, the availability of [D-Phe⁶,-Ala¹¹,Phe¹³,Nle¹⁴]Bn-(6-14), which functions as a high affinity agonist in conjunction with hBRS-3-transfected cell lines and the recognition of three classes of receptor antagonists including one with affinity of 0.5 µM, should provide important tools to assist in the identification of its natural ligand, the development of more potent selective receptor antagonists and agonists, and further exploration of the signaling properties of the hBRS-3 receptor.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				G. Song, M. C. Satterfield, J. Kim, F. W. Bazer, and T. E. Spencer Gastrin-Releasing Peptide (GRP) in the Ovine Uterus: Regulation by Interferon Tau and Progesterone Biol Reprod, August 1, 2008; 79(2): 376 - 386. [Abstract] [Full Text] [PDF]

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]

				N. Gonzalez, S. J. Hocart, S. Portal-Nunez, S. A. Mantey, T. Nakagawa, E. Zudaire, D. H. Coy, and R. T. Jensen Molecular Basis for Agonist Selectivity and Activation of the Orphan Bombesin Receptor Subtype 3 Receptor J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 463 - 474. [Abstract] [Full Text] [PDF]

				S. A. Mantey, N. Gonzalez, M. Schumann, T. K. Pradhan, L. Shen, D. H. Coy, and R. T. Jensen Identification of Bombesin Receptor Subtype-Specific Ligands: Effect of N-Methyl Scanning, Truncation, Substitution, and Evaluation of Putative Reported Selective Ligands J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 980 - 989. [Abstract] [Full Text] [PDF]

				S. A. Mantey, D. H. Coy, L. K. Entsuah, and R. T. Jensen Development of Bombesin Analogs with Conformationally Restricted Amino Acid Substitutions with Enhanced Selectivity for the Orphan Receptor Human Bombesin Receptor Subtype 3 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1161 - 1170. [Abstract] [Full Text] [PDF]

				C. Dumesny, J. C. Whitley, G. S. Baldwin, A. S. Giraud, and A. Shulkes Developmental expression and biological activity of gastrin-releasing peptide and its receptors in the kidney Am J Physiol Renal Physiol, September 1, 2004; 287(3): F578 - F585. [Abstract] [Full Text] [PDF]

				A. MartInez, M. Julian, C. Bregonzio, L. Notari, T. W. Moody, and F. Cuttitta Identification of Vasoactive Nonpeptidic Positive and Negative Modulators of Adrenomedullin Using a Neutralizing Antibody-Based Screening Strategy Endocrinology, August 1, 2004; 145(8): 3858 - 3865. [Abstract] [Full Text] [PDF]

				M. Subramaniam, K. Sugiyama, D. H. Coy, Y. Kong, Y. E. Miller, P. F. Weller, K. Wada, E. Wada, and M. E. Sunday Bombesin-like Peptides and Mast Cell Responses: Relevance to Bronchopulmonary Dysplasia? Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 601 - 611. [Abstract] [Full Text] [PDF]

				K. Cheng, S. Khurana, Y. Chen, R. H. Kennedy, P. Zimniak, and J.-P. Raufman Lithocholylcholine, a Bile Acid/Acetylcholine Hybrid, Is a Muscarinic Receptor Antagonist J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 29 - 35. [Abstract] [Full Text] [PDF]

				J. C. Reubi, S. Wenger, J. Schmuckli-Maurer, J.-C. Schaer, and M. Gugger Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[D-TYR6, {beta}-ALA11, PHE13, NLE14] Bombesin(6-14) Clin. Cancer Res., April 1, 2002; 8(4): 1139 - 1146. [Abstract] [Full Text] [PDF]

				R. R. Ryan, T. Katsuno, S. A. Mantey, T. K. Pradhan, H. C. Weber, D. H. Coy, J. F. Battey, and R. T. Jensen Comparative Pharmacology of the Nonpeptide Neuromedin B Receptor Antagonist PD 168368 J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1202 - 1211. [Abstract] [Full Text]

				X. Jian, E. Sainz, W. A. Clark, R. T. Jensen, J. F. Battey, and J. K. Northup The Bombesin Receptor Subtypes Have Distinct G Protein Specificities J. Biol. Chem., April 23, 1999; 274(17): 11573 - 11581. [Abstract] [Full Text] [PDF]

				S. A. Mantey, D. H. Coy, T. K. Pradhan, H. Igarashi, I. M. Rizo, L. Shen, W. Hou, S. J. Hocart, and R. T. Jensen Rational Design of a Peptide Agonist That Interacts Selectively with the Orphan Receptor, Bombesin Receptor Subtype 3 J. Biol. Chem., March 16, 2001; 276(12): 9219 - 9229. [Abstract] [Full Text] [PDF]